Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Alzheimer's Disease

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 26 articles:
HTML format



Single Articles


    February 2024
  1. MAYEUX R
    Alzheimer's Disease Biomarkers - Timing Is Everything.
    N Engl J Med. 2024;390:761-763.
    PubMed    


  2. JIA J, Ning Y, Chen M, Wang S, et al
    Biomarker Changes during 20 Years Preceding Alzheimer's Disease.
    N Engl J Med. 2024;390:712-722.
    PubMed     Abstract available


    January 2024
  3. REZAI AR, D'Haese PF, Finomore V, Carpenter J, et al
    Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease.
    N Engl J Med. 2024;390:55-62.
    PubMed     Abstract available


    November 2023

  4. Alzheimer's Update, Part 2: ITT Episode 21.
    N Engl J Med. 2023;389:e43.
    PubMed    


  5. SCHNEIDER LS
    What the Gantenerumab Trials Teach Us about Alzheimer's Treatment.
    N Engl J Med. 2023;389:1918-1920.
    PubMed    


  6. BATEMAN RJ, Smith J, Donohue MC, Delmar P, et al
    Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
    N Engl J Med. 2023;389:1862-1876.
    PubMed     Abstract available



  7. Alzheimer's Update, Part 1: ITT Episode 20.
    N Engl J Med. 2023;389:e33.
    PubMed    


    July 2023
  8. SPERLING RA, Donohue MC, Raman R, Rafii MS, et al
    Trial of Solanezumab in Preclinical Alzheimer's Disease.
    N Engl J Med. 2023 Jul 17. doi: 10.1056/NEJMoa2305032.
    PubMed     Abstract available


    April 2023
  9. VAN DYCK CH, Sabbagh M, Cohen S
    Lecanemab in Early Alzheimer's Disease. Reply.
    N Engl J Med. 2023;388:1631-1632.
    PubMed    


  10. BRENMAN JE
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1631.
    PubMed    


  11. POMARA N, Imbimbo BP
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1630-1631.
    PubMed    


  12. VALENZUELA MJ, Pascual-Leone A
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1630.
    PubMed    


  13. ZENG BS, Tseng PT, Liang CS
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1630.
    PubMed    


    January 2023
  14. GANDY S, Ehrlich ME
    Moving the Needle on Alzheimer's Disease with an Anti-Oligomer Antibody.
    N Engl J Med. 2023;388:80-81.
    PubMed    


  15. SABBAGH M, van Dyck CH
    Response to: Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.
    N Engl J Med. 2023 Jan 4:10.1056/NEJMc2215907#sa1. doi: 10.1056/NEJMc2215907.
    PubMed    


    November 2022
  16. VAN DYCK CH, Swanson CJ, Aisen P, Bateman RJ, et al
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2022 Nov 29. doi: 10.1056/NEJMoa2212948.
    PubMed     Abstract available


    November 2021
  17. SACHS RE, Bagley N
    Medicare Coverage of Aducanumab - Implications for State Budgets.
    N Engl J Med. 2021;385:2019-2021.
    PubMed    


  18. ROBINSON JC
    Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform.
    N Engl J Med. 2021;385:2017-2019.
    PubMed    


    August 2021
  19. ALEXANDER GC, Knopman DS, Emerson SS, Ovbiagele B, et al
    Revisiting FDA Approval of Aducanumab.
    N Engl J Med. 2021;385:769-771.
    PubMed    


  20. MINTUN MA, Wessels AM, Sims JR
    Donanemab in Early Alzheimer's Disease. Reply.
    N Engl J Med. 2021;385:667.
    PubMed    


  21. ESPAY AJ
    Donanemab in Early Alzheimer's Disease.
    N Engl J Med. 2021;385:666-667.
    PubMed    


    July 2021
  22. RABINOVICI GD
    Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMp2111320.
    PubMed    


  23. DUNN B, Stein P, Temple R, Cavazzoni P, et al
    An Appropriate Use of Accelerated Approval - Aducanumab for Alzheimer's Disease.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMc2111960.
    PubMed    


    May 2021
  24. LEVEY AI
    Progress with Treatments for Alzheimer's Disease.
    N Engl J Med. 2021;384:1762-1763.
    PubMed    


    March 2021
  25. MINTUN MA, Lo AC, Duggan Evans C, Wessels AM, et al
    Donanemab in Early Alzheimer's Disease.
    N Engl J Med. 2021 Mar 13. doi: 10.1056/NEJMoa2100708.
    PubMed     Abstract available


    October 2020
  26. FRIED LP, Rowe JW
    Health in Aging - Past, Present, and Future.
    N Engl J Med. 2020;383:1293-1296.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.